# A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct02692716` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02692716](<https://clinicaltrials.gov/study/NCT02692716>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02692716

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3183 participants.

## Technical summary

Registry record NCT02692716. Randomized; double masking; primary purpose treatment. Start 2017-01-17 (actual); primary completion 2018-09-25 (actual). Results posted on 2020-02-27.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3183 participants (enrolled count; ClinicalTrials.gov record NCT02692716, source copy `cardio:ctgov-nct02692716-2022-07-20`, retrieved 2026-10-26)
- Started: 2017-01-17 (actual) (ClinicalTrials.gov record NCT02692716, source copy `cardio:ctgov-nct02692716-2022-07-20`, retrieved 2026-10-26)
- Primary completion: 2018-09-25 (actual) (ClinicalTrials.gov record NCT02692716, source copy `cardio:ctgov-nct02692716-2022-07-20`, retrieved 2026-10-26)
- Completion: 2018-09-25 (actual) (ClinicalTrials.gov record NCT02692716, source copy `cardio:ctgov-nct02692716-2022-07-20`, retrieved 2026-10-26)
- Results first posted: 2020-02-27 (ClinicalTrials.gov record NCT02692716, source copy `cardio:ctgov-nct02692716-2022-07-20`, retrieved 2026-10-26)
- Countries: United States; Algeria; Argentina; Brazil; Canada; Denmark; Germany; India; Israel; Italy; Malaysia; Mexico; Netherlands; Poland; Romania; South Africa; Spain; Taiwan; Thailand; Türkiye; United Kingdom (ClinicalTrials.gov record NCT02692716, source copy `cardio:ctgov-nct02692716-2022-07-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02692716-2022-07-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
- Acronym: PIONEER 6
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): semaglutide
- Intervention (Drug): placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (`cardio:pubmed-31185157`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c00b8694ef310a5c6f37b964bc416a7105bc892144f29e1a0d7ad4db333a6ae6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
